No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
62 |
4. Check minimum number of eventsNone |
62 |
5. Include endpointsNone |
62 |
6. Filter based on genotype QC (FinnGen only) |
59 |
Control definitions (FinnGen only)
- Control exclude
- IBD_CMV
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Cytomegaloviral pneumonitis
based on the number of shared cases.
Similar with more cases:
- Cytomegalovirus infection, IBD co-morbidity
- Cytomegaloviral disease
- Infections, IBD-co-morbidities
- Other viral diseases
- Other viral diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 414 | 182 | 224 |
| Only index persons | 268 | 122 | 146 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.00 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 59.56 | 58.58 | 60.46 |
| Only index persons | 63.16 | 60.88 | 65.06 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 59 | 24 | 35 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.02 |
| Median age at first event (years) | 67.48 | 64.41 | 69.59 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 62
- Matched controls
- 620
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
J17.1*B25.0
ICD-10 Finland
Cytomegaloviral pneumonitis
+∞
49.9
41
*
B25.0
ICD-10 Finland
Cytomegaloviral pneumonitis
+∞
29.5
26
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
13.0
22.1
46
112
TGC00
NOMESCO Finland
Bronchial lavation
55.3
19.2
22
6
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
10.1
19.1
33
63
UGC12
NOMESCO Finland
Flexible bronchoscopy
24.1
18.6
27
19
H02AB04
ATC
methylprednisolone; systemic
9.0
16.6
29
55
127
Kela drug reimbursment
Transplant complication
193.8
15.2
15
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
17.0
13.1
21
18
L04AA06
ATC
mycophenolic acid; systemic
48.4
12.9
15
*
JN4AD
NOMESCO Finland
Body CT examination
8.0
12.7
22
40
L04AD01
ATC
ciclosporin; systemic
59.1
12.5
14
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
11.5
11.4
22
28
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
16.3
11.2
18
15
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
7.3
11.0
20
38
B25.9
ICD-10 Finland
Cytomegaloviral disease, unspecified
+∞
10.7
10
*
TK800
NOMESCO Finland
Hemodialysis
25.2
10.4
14
7
GD1AA
NOMESCO Finland
Thorax X-ray examination
6.9
10.3
49
219
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
11.9
10.2
19
22
C03CA01
ATC
furosemide; systemic
5.4
9.8
40
156
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
117.2
9.7
10
*
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
9.0
9.2
20
31
R50.9
ICD-10 Finland
Fever, unspecified
5.6
9.1
23
59
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
6.1
8.8
19
42
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
10.7
8.8
17
21
XW000
NOMESCO Finland
Bone marrow biopsy
17.8
8.7
13
9
Z94.0
ICD-10 Finland
Kidney transplant status
+∞
8.5
8
*
J17.3*B59
ICD-10 Finland
Pneumonia due to Pneumocystis carinii
+∞
8.5
8
*
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
8.5
8
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
9.0
7.6
16
23
L04AX01
ATC
azathioprine; systemic
18.7
7.5
11
7
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
7.9
7.4
17
28
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
+∞
7.4
7
*
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
+∞
7.4
7
*
L04AA01
ATC
[U] ciclosporin
+∞
7.4
7
*
B25.8
ICD-10 Finland
Other cytomegaloviral diseases
+∞
7.4
7
*
WX882
NOMESCO Finland
High dependency care
23.4
7.4
10
5
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
23.4
7.4
10
5
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
34.5
7.4
9
*
J01MA12
ATC
levofloxacin; systemic
4.4
7.0
24
78
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
45.1
6.9
8
*
A02BC02
ATC
pantoprazole; systemic
6.1
6.9
55
348
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
14.5
6.9
11
9
WX892
NOMESCO Finland
Monitored bed care
9.2
6.9
14
19
GD1AD
NOMESCO Finland
Thorax CT examination
9.9
6.7
13
16
A12AA04
ATC
calcium carbonate; oral
77.5
6.6
7
*
Z01.8
ICD-10 Finland
Other specified special examinations
4.3
6.5
22
70
B03XA02
ATC
darbepoetin alfa; parenteral
20.7
6.5
9
5
L04AD02
ATC
tacrolimus; systemic
+∞
6.3
6
*
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
+∞
6.3
6
*
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
+∞
6.3
6
*
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
+∞
6.3
6
*
J80
ICD-10 Finland
Adult respiratory distress syndrome
+∞
6.3
6
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.0
6.2
24
84
J01MA14
ATC
moxifloxacin; systemic
6.1
6.2
17
36
A28
ICPC
Limited function/disability NOS
4.3
6.1
20
62
N17.9
ICD-10 Finland
Acute renal failure, unspecified
12.9
6.0
10
9
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
37
55
15.20
27.28
4.0
1.9
—
—
—
0
0
36
53
14.81
26.64
3.6
1.8
—
—
—
0
0
33
16
42.25
26.41
3.0
1.8
—
—
—
0
0
32
16
39.60
25.25
3.0
1.8
—
—
—
0
0
42
82
13.78
24.78
4.4
2.1
—
—
—
0
0
27
12
38.49
21.49
2.4
1.7
—
—
—
0
0
25
9
45.13
20.79
2.7
2.2
—
—
—
0
0
25
9
45.13
20.79
2.7
2.2
—
—
—
0
0
24
11
34.47
18.71
2.1
1.6
—
—
—
0
0
23
9
39.43
18.61
2.1
1.6
—
—
—
0
0
24
14
26.98
17.42
6.8
2.1
—
—
—
0
0
19
6
44.49
15.93
3.0
1.7
—
—
—
0
0
19
6
44.49
15.93
3.0
1.7
—
—
—
0
0
29
60
8.20
15.15
17.1
7.7
1.28
1.51
mmol/l
0.13
19
44
20
11
26.03
14.58
2.3
1.7
—
—
—
0
0
22
36
8.92
14.03
2.6
1.6
—
—
—
0
0
18
13
18.90
11.89
3.2
1.7
—
—
—
0
0
16
8
26.28
11.87
2.6
2.1
—
—
—
0
0
16
8
26.28
11.87
2.6
2.1
—
—
—
0
0
17
11
20.68
11.65
3.0
1.2
—
—
—
0
0
14
6
29.46
10.80
1.9
1.3
—
—
—
0
0
24
56
6.36
10.73
8.9
3.5
0.23
2.38
mmol/l
1.83
15
40
26
71
5.58
9.70
4.9
2.3
24.92
21.96
%
0.43
18
62
13
8
20.09
9.01
3.6
1.3
—
—
—
0
0
50
251
6.13
8.54
34.0
6.7
1.19
1.21
mmol/l
0.61
43
208
7
0
+∞
7.43
1.4
0.0
—
—
—
0
0
46
239
4.58
6.91
25.5
3.9
32.27
35.11
g/l
1.93
40
221
48
261
4.72
6.69
25.8
14.6
1.13
1.26
inr
0.55
11
83
10
7
16.67
6.65
1.9
1.4
—
—
—
0
0
16
41
4.91
6.17
2.4
3.0
66.15
66.08
g/l
0.01
11
35
8
6
15.02
5.23
2.0
1.2
—
—
—
0
0
8
7
12.86
4.93
1.6
2.4
—
—
—
0
0
8
7
12.86
4.93
1.6
2.4
—
—
—
0
0
8
7
12.86
4.93
1.6
2.4
—
—
—
0
0
40
223
3.24
4.70
7.5
2.4
—
—
—
0
0
9
12
8.55
4.53
2.9
1.0
—
—
—
0
0
17
59
3.59
4.31
8.2
3.0
22.42
9.05
umol/l
0.58
12
52
7
7
11.06
4.12
4.1
1.1
—
—
—
0
0
27
128
2.97
4.10
1.4
1.5
14.74
20.67
nmol/l
2.52
22
103
6
5
13.07
3.84
2.5
1.4
—
—
—
0
0
6
5
13.07
3.84
1.3
3.0
—
—
—
0
0
6
5
13.07
3.84
2.8
1.0
—
—
—
0
0
10
21
5.46
3.74
14.1
3.5
24.51
25.65
mmol/l
—
10
21
7
9
8.58
3.66
1.9
1.1
—
—
—
0
0
8
13
6.88
3.63
1.5
1.2
—
—
—
0
0
28
144
2.72
3.56
5.1
2.8
0.54
0.46
e6/l
0.06
22
114
35
203
2.66
3.49
4.9
2.4
321.43
151.38
ug/l
1.47
35
180
33
186
2.66
3.48
7.3
2.9
—
—
—
0
0
6
8
8.14
3.13
14.0
1.9
53.50
60.50
%
—
6
8
7
12
6.41
3.11
1.3
1.3
—
—
—
0
0
34
204
2.48
3.04
1.9
1.9
97.31
96.19
pmol/l
0.05
18
106
5
5
10.71
3.03
1.2
1.2
—
—
—
0
0
17
73
2.83
2.97
4.4
2.7
1.09
2.66
e6/l
—
10
41
53
409
3.03
2.82
31.9
7.6
99.17
79.95
u/l
0.50
53
383
5
6
8.92
2.80
1.2
6.3
—
—
—
0
0
5
6
8.92
2.80
1.2
1.0
—
—
—
0
0
17
76
2.70
2.75
4.4
2.6
0.53
0.66
e6/l
—
10
44
51
382
2.89
2.69
13.3
4.2
26.04
11.85
mm/h
4.18
51
339
6
11
5.90
2.61
1.3
1.5
—
—
—
0
0
10
37
3.02
2.19
11.7
5.1
24.49
25.04
mmol/l
—
10
37
20
109
2.23
2.09
1.8
1.7
1170.07
1340.56
nmol/l
0.31
15
83
14
68
2.37
1.88
8.6
7.7
104.21
103.88
mmol/l
0.07
14
68
7
23
3.29
1.86
1.6
4.3
62.71
409.35
u/ml
—
7
17
19
106
2.14
1.85
4.2
2.3
—
—
—
0
0
6
19
3.38
1.70
4.5
2.5
—
—
—
0
0
5
14
3.78
1.65
6.6
2.2
65.20
77.21
u/ml
—
5
14
5
14
3.78
1.65
1.0
1.2
—
—
—
0
0
26
172
1.88
1.56
7.1
3.9
53.99
10.52
mg/mmol
0.61
21
109
32
231
1.80
1.42
5.5
4.2
29.92
27.98
ng/l
0.12
26
174
9
42
2.33
1.41
2.4
3.0
21.11
30.18
u/l
—
9
34
36
270
1.79
1.40
3.8
3.0
—
—
—
0
0
12
62
2.16
1.39
5.6
3.6
—
—
—
0
0
7
30
2.50
1.16
1.4
1.2
—
—
—
0
0
7
30
2.50
1.16
4.9
3.0
0.91
1.19
%
—
7
30
25
181
1.64
1.03
4.0
3.2
2359.15
1048.11
ng/l
0.96
25
145
19
129
1.68
0.99
1.7
1.7
515.92
462.94
pmol/l
0.62
12
110
33
258
1.60
0.99
6.6
3.8
0.00
0.00
estimate
—
8
51
6
30
2.10
0.89
2.0
2.0
—
—
—
0
0
32
253
1.55
0.88
6.8
3.8
0.00
0.02
estimate
—
8
59
12
75
1.74
0.82
1.4
1.5
—
—
—
0
0
6
33
1.90
0.81
4.5
4.3
49.07
47.10
%
—
6
33
32
258
1.50
0.78
10.0
5.1
0.00
0.00
estimate
—
8
53
19
250
0.65
0.75
3.5
5.5
1.86
2.01
ug/l
0.13
19
222
43
482
0.65
0.74
46.7
14.4
59.11
78.44
ml/min/173m2
3.68
36
387
5
27
1.92
0.70
1.4
2.4
0.02
0.14
e6/l
—
5
27
18
136
1.46
0.58
2.2
1.7
1.60
1.37
mmol/l
0.90
18
110
25
204
1.38
0.52
6.1
4.0
—
—
—
0
0
16
204
0.71
0.50
3.1
4.6
29.43
21.15
%
—
10
102
56
534
1.50
0.36
75.6
17.0
4.03
3.99
mmol/l
0.47
56
519
56
532
1.54
0.36
74.3
17.0
138.71
139.67
mmol/l
1.64
56
518
7
55
1.31
0.31
3.4
5.2
2.44
7.82
ug/l
—
7
44
56
540
1.38
0.26
40.5
10.7
25.29
25.94
u/l
0.15
56
517
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
56
541
1.36
0.16
64.0
17.6
119.52
81.15
umol/l
2.45
56
541
50
481
1.20
0.16
9.4
6.5
42.27
40.84
mmol/mol
0.42
45
438
16
153
1.06
0.01
5.4
4.0
0.00
0.00
estimate
—
6
50
50
499
1.01
0.00
7.2
4.8
6.22
6.03
mmol/l
0.36
45
444
37
375
0.97
0.00
3.2
3.7
15.30
14.87
pmol/l
0.50
37
325
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.3
—
44.71
—
0
8
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
57
561
1.20
-0.00
88.5
22.4
121.86
135.95
g/l
6.30
57
550
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
6
66
0.90
-0.00
11.8
8.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
57
561
1.20
-0.00
88.5
22.3
37.80
40.27
%
2.17
47
528
Mortality – FinRegistry
↥Association
Association between endpoint CMV_PNEUMONIA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CMV_PNEUMONIA | 10.122 [4.72, 21.71] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.105 |
During the follow-up period (1.1.1998 — 31.12.2019), 54 out of 114 females with CMV_PNEUMONIA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CMV_PNEUMONIA | 5.501 [3.25, 9.32] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 55 out of 111 males with CMV_PNEUMONIA died.
Mortality risk
Mortality risk for people of age
years, who have CMV_PNEUMONIA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.989% | 1.02% |
| 5 | 5.265% | 5.537% |
| 10 | 13.387% | 14.094% |
| 15 | 25.115% | 23.732% |
| 20 | 38.525% | 37.855% |
Relationships between endpoints
↥Index endpoint: CMV_PNEUMONIA – Cytomegaloviral pneumonitis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data